EVLO News and Press, Evelo Biosciences Inc. From 02/03/22

Palm Beach, FL –– February 3, 2022  – FinancialNewsMedia.com News Commentary – Multiple Sclerosis (MS) is an immune-mediated disease of the central nervous system. It is characterized by demyelination, inflammation, and degenerative changes such ...

CAMBRIDGE, Mass., Jan. 17, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced data for EDP1815, the Company ...

CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced its strategic priorities and upcom...

In its annual selection of selecting constituents, NASDAQ Biotechnology Index added Evelo Biosciences (NASDAQ:EVLO) to its list, effective Dec.20 before market open. The NASDAQ Biotechnology Index is calculated under a modified capitalization-weighted methodology. Companies in the NASDAQ Biot...

CAMBRIDGE, Mass., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced that the Company has been added to...

The shares of Seres Therapeutics (MCRB +18.6%) have reached the highest level in more than four months after the company announced the enrollment of the first patient in an early-stage study for microbiome therapy SER-155 in graft-versus-host disease ((GvHD)). Conducted in partnership with Me...

CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced that management will host a firesi...

Shares of Evelo Biosciences (EVLO +22.7%) are up this morning after Chardan Capital Markets upgraded the stock from neutral to buy. Analyst Keay Nakae is maintaining the price target at $12 (~36% upside). The company's lead candidate, EDP1815, is in phase 2/3 for COVID-19 and phase 2 for psor...

Image source: The Motley Fool. Evelo Biosciences, Inc. (NASDAQ: EVLO) Q3 2021 Earnings Call Oct 28, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Evelo Biosciences, Inc. (EVLO) Q3 2021 Earnings Call Transcript

Evelo Biosciences, Inc. (EVLO) Q3 2021 Earnings Conference Call October 28, 2021 8:30 AM ET Company Participants Kendra Sweeney - Investor Relations Simba Gill - Chief Executive Officer Mark Plinio - Chief Commercial Officer Jonathan Zung - Chief Development Officer Conference Call Participan...